Sodium-glucose co-transporter-2 inhibitors: An emerging new class of oral antidiabetic drug

Diabetes, Obesity and Metabolism

Volumn 11, Issue 2, 2009, Pages 79-88

  Idris, Iskandar ^a   Donnelly, Richard ^b  

^a SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Diabetes; SGLT2 inhibition; Therapy

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; AVE 2268; DAPAGLIFLOZIN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; ISIS 388626; JNJ 28431754; METFORMIN; ORAL ANTIDIABETIC AGENT; PHLORIZIN; PLACEBO; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; FLATULENCE; GENE EXPRESSION; GENE MUTATION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; MONOTHERAPY; NAUSEA; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POLYURIA; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 58149357463     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00982.x     Document Type: Review

References (53)

1. Petersen C. Analyse des phloridzins. Annales Academie Science Francaise 1835; 15: 178.
2. Stiles PG, Lusk G. On the action of phlorizin. Am J Physiol 1903; 10: 61-79
3. Chassis H, Joliffe N, Smith H. The action of phlorizin on the excretion on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest 1933; 12: 1083-1089.
4. Keller DM, Lotspeich WD. Effect of phlorizin on the osmotic behaviour of mitochondria in isotonic sucrose. J Biol Chem 1959; 234: 991-994.
5. Alvarado FC, Crane RK. Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine in vitro. Biochim Biophys Acta 1962; 56: 170-172.
6. Lee WS, Wells RG, Hediger MA. The high affinity Na/glucose cotransporter. Re-evaluation and distribution of expression. J Biol Chem 1994; 269: 12032-12039.
7. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J. Phlorizin: A review. Diabetes Metab Res Rev 2005; 21: 31-38.
8. Rosetti L, Zawalich W, DeFronzo RA. Effect of chronic hyperglycaemia on in-vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987; 80: 1037-1044.
9. Rosetti L, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycaemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510-1515.
10. Fisher SJ, Lekas M, Shi ZQ et al. Insulin-independent acute restoration of euglycemia normalizes the impaired glucose clearance during exercise in diabetic dogs. Diabetes 1997; 46: 1805-1812.
11. Shepherd PR, Kahn BB. Glucose transporters and insulin action. N Engl J Med 1999; 341: 248-259.
12. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): Expanded families of sugar transport proteins. Br J Nutr 2003; 89: 3-9.
13. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93: 397-404.
14. Mackenzie B, Loo DD, Panayotova-Heiermann M, Wright EM. Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2. J Biol Chem 1996; 20: 32678-32683.
15. +-glucose cotransporters. Am J Physiol 2001; 280: F10-F18
16. Zhou L, Cryan EV, D'Andrea MR, Belkowski S, Conway BR, Demarest KT. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem 2003; 90: 339-346.
17. Evans S, Grasset E, Heyman M, Dumontier AM, Beau JP, Desjeux J-F. Congenital selective malabsorption of glucose and galactose. J Pediatr Gastroenterol Nutr 1985; 4: 878-886.
18. Oku A, Ueta K, Arakawa K et al. T-1095, an inhibitor of renal Na+ -glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794-1800.
19. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity/high-capacity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-76.
20. Handlon AL. Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents. Expert Opin Ther Patents 2005; 15: 1531-1540.
21. Asano T, Anai M, Sakoda H. SGLT as a therapeutic target. Drugs Fut 2004; 29: 461-466.
22. Ueta K, Ishihara T, Matsumoto Y et al. Long-term treatment with the Na+ -glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 2005; 22: 2655-2668.
23. Adachi T, Yasuda K, Okamoto Y. T-1095, a renal Na glucose cotransporter inhibitor, improves hyperglycaemia in streptozotocin-induced diabetic rats. Metabolism 2000; 49: 990-995.
24. Santer R, Kinner M, Lassen CL et al. Molecular analysis of the SGLT2 gene in patients with renal glycosuria. J Am Soc Nephrol 2003; 14: 2873-2882.
25. Heilig CW, Brosius FC 3rd, Henry DN. Glucose transporters of the glomerulus and the implications for diabetic nephropathy. Kidney Int Suppl 1997; 60: S91-S99.
26. Vestri S, Okamoto MM, de Freitas HS et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 2001; 182: 105-112.
27. Marks J, Carvou NJ, Debnam ES, Srai SK, Unwin RJ. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 2003; 553: 137-145.
28. Arakawa K, Ishihara T, Oku A et al. Improved diabetic syndrome in C57BL/ KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001; 132: 578-586.
29. Katsuno K, Fujimori Y, Takemura Y et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007; 320: 323-330.
30. Ghosh S, Shen Y, Harrington WW et al. Metabolic responses to a sodium-glucose transporter-2 inhibitor, GW869682, assessed by whole-genome transcript profiling. Diabetologia 2007; 50(Suppl. 1): S376
31. Whaley J, Hagan D, Taylor J et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2007; A149
32. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149.
33. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729.
34. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity/high capacity SGLT2 inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-76.
35. Harrington WW, Milliken N, Binz JG et al. Remogliflozin etabonate, a potent and selective sodium-dependent glucose transporter 2 antagonist, produced sustained metabolic effects in Zucker Diabetic Fatty rats. Diabetes 2008; 57 (Suppl. 1): A157.
36. Wancewicz EV, Siwkowski A, Meibohm B et al. Long term safety and efficacy of ISIS-388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species. Diabetes 2008; 57 (Suppl. 1): A96.
37. Komoroski B, Brenner E, Li L, Vach-Harajani N, Kornhauser D. Dapagliflozin (BMS-512148), a selective inhibitor of the sodium-glucose uptake transporter 2 (SGLT2), reduces fasting serum glucose and glucose excursion in type 2 diabetes mellitus patients over 14 days. Diabetes 2007 (Suppl.): A49
38. Bristol Myers-Squibb. Clinical trials disclosure: Clinical trials for metabolic disease. http://ctr.bms.com/ctd/InitTrialAction.do?linkname= Metabolics&type=pharma&sortby
39. List JF, Woo VC, Villegas EM, Tang W, Fiedorek FT. Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatment-naïve patients with type 2 diabetes. Diabetes 2008; 57 (Suppl. 1): A94.
40. Hussey EK, Dobbins RL, Stolz RR et al. A double-blind randomized repeat dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy overweight and obese subjects. Diabetes 2007 (Suppl.): A131.
41. Kler L, Hussey EK, Dobbins RL et al. Clinical studies to assess safety, pharmacokinetics and pharmacodynamics of sergliflozin, a novel inhibitor of glucose reabsorption. Diabetologia 2007; 50 (Suppl. 1): S378.
42. O'Connor-Semmes RL, Hussey EK, Murray SC et al. Dose regimen optimization for a novel therapeutic drug (SGLT inhibitor) using a physiological pharmacokinetic-pharmacodynamic model incorporating both human and in-vitro data. Diabetes 2007 (Suppl.): A128.
43. Ludvigsson J. Why diabetes incidence increases-a unifying theory. Ann N Y Acad Sci 2006; 1079: 374-382.
44. Anthony K, Reed LJ, Dunn JT et al. Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: The cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes 2006; 55: 2986-2992.
45. Kennedy RL, Chokkalingam K, Farshchi HR. Nutrition in patients with Type 2 diabetes: Are low-carbohydrate diets effective, safe or desirable? Diabet Med 2005; 22: 821-832.
46. Geerlings SE, Stolk RP, Camps MJ, et al. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000; 23: 1737-1741.
47. Betz AL, Drewes LR, Gilboe DD. Inhibition of glucose transport into brain by phlorizin, phloretin and glucose analogues. Biochim Biophys Acta 1975; 406: 505-515.
48. Yang XJ, Kow LM, Funabashi T, Mobbs CV. Hypothalamic glucose sensor: similarities to and differences from pancreatic beta-cell mechanisms. Diabetes 1999; 48: 1763-1772.
49. Elfeber K, Köhler A, Lutzenburg M et al. Localization of the Na+ -D-glucose cotransporter SGLT1 in the blood-brain barrier. Histochem Cell Biol 2004; 121: 201-207.
50. Nishizaki T, Kammesheidt A, Sumikawa K, Asada T, Okada Y. A sodium- and energy-dependent glucose transporter with similarities to SGLT1-2 is expressed in bovine cortical vessels. Neurosci Res 1995; 22: 13-22.
51. Hall JT, Reilly RT, Cottrill KL, Stone WS, Gold PE. Phlorizin enhancement of memory in rats and mice. Pharmacol Biochem Behav 1992; 41: 295-299.
52. Boccia MM, Kopf SR, Baratti CM. Phlorizin, a competitive inhibitor of glucose transport, facilitates memory storage in mice. Neurobiol Learn Mem 1999; 71: 104-112.
53. Suzuki S, Noda M, Sugita M, Tsubochi H, Fujimura S. Difference in the effect of phloridzin on alveolar fluid absorption in anesthetized rats and in ex vivo rat lungs. Exp Lung Res 1999; 25: 393-406.